PLD
45
5
WBA
44
6
VZ
30
5
TXT
48
2
XRAY
34
3
KIM
58
-2
WMT
70
2
M
55
7
PEP
33
-3
DLTR
59
4
KHC
13
-2
CNP
52
-2
ZTS
43
3
PHM
50
2
XRX
57
-2
QCOM
57
-2
NTRS
47
3
EQT
45
-3
PYPL
52
2
NUE
43
2
PLD
45
5
WBA
44
6
VZ
30
5
TXT
48
2
XRAY
34
3
KIM
58
-2
WMT
70
2
M
55
7
PEP
33
-3
DLTR
59
4
KHC
13
-2
CNP
52
-2
ZTS
43
3
PHM
50
2
XRX
57
-2
QCOM
57
-2
NTRS
47
3
EQT
45
-3
PYPL
52
2
NUE
43
2
Financhill
Back

Janux Therapeutics 10K Form

Sell
29

JANX
Janux Therapeutics

Last Price:
$54.19
Seasonality Move:
84.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive JANX News And Ratings

See the #1 stock for the next 7 days that we like better than JANX

JANX Financial Statistics

Sales & Book Value

Annual Sales: $8.1M
Cash Flow: $-2.3M
Price / Cash Flow: 0
Annual Sales: $12.54
Price / Book: 4.41

Profitability

EPS (TTM): -1.16000
Net Income (TTM): $-60.5M
Gross Margin: --
Return on Equity: -11.37%
Return on Assets: -10.65%

Janux Therapeutics Earnings Forecast

Key Janux Therapeutics Financial Ratios

  • The Research & Development expenses have been 679.48% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of JANX is -721.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Janux Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: JANX
Website: januxrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 38.8
Quick Ratio: 38.58

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

JANX Technical Analysis vs Fundamental Analysis

Sell
29
Janux Therapeutics (JANX) is a Sell

Is Janux Therapeutics a Buy or a Sell?